Track GRAIL, LLC — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

GRAIL, LLC GRAL Open GRAIL, LLC in new tab

60.71 USD
EPS
-10.30
P/B
0.95
ROE
-16.09
Target Price
66.86 USD
GRAIL, LLC logo

GRAIL, LLC

🧾 Earnings Recap – Q3 2025

GRAIL reported strong third-quarter performance, with a 39% increase in Gallery volume and a 29% increase in revenue year-over-year, reflecting robust uptake and strategic developments in key markets.

  • Gallery tests are growing in adoption, with approximately 420,000 tests sold across over 16,000 healthcare providers.
  • Strategic collaboration announced with Samsung to commercialize Gallery in South Korea and other Asian markets, alongside a $110 million equity investment from Samsung.
  • Successfully launched Gallery in Canada through a partnership with MedCan, expanding market presence.
  • Completed a $325 million private placement to strengthen financial position as the company progresses towards key milestones.
  • Positive results from PATHFINDER II study showcased substantial cancer detection improvements, underscoring Gallery’s effectiveness in early cancer diagnosis.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 19, 2026
EPS-10.30
Book Value63.92
Price to Book0.95
Debt/Equity2.04
% Insiders4.722%
Growth
Revenue Growth0.28%
Estimates
Forward P/E-6.62
Forward EPS-9.18
Target Mean Price66.86

DCF Valuation

Tweak assumptions to recompute fair value for GRAIL, LLC (GRAL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

GRAIL, LLC Logo GRAIL, LLC Analysis (GRAL)

United States Healthcare Official Website Stock

Is GRAIL, LLC a good investment? GRAIL, LLC (GRAL) is currently trading at 60.71 USD. Market analysts have a consensus price target of 66.86 USD. This suggests a potential upside from current levels.

Earnings Schedule: GRAIL, LLC is expected to release its next earnings report on May 19, 2026. The market consensus estimate for Forward EPS is -9.18.

Investor FAQ

Does GRAIL, LLC pay a dividend?

No, it does not currently pay a dividend.

What asset class is GRAIL, LLC?

GRAIL, LLC is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 19, 2026. The company currently has a trailing EPS of -10.30.

Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Exchange Ticker
None GRAL

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion